Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.
Catherine Shaffer
Advertisement
Catherine Shaffer is a contributing writer to BioPharm International, cathshaffer@gmail.com.
Articles by Catherine Shaffer
A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.
Advertisement
Latest Updated Articles
Ensuring the Biological Integrity of Raw MaterialsFebruary 1st 2017
Advertisement
Advertisement